We are developing a therapy to stop glioblastoma by targeting the Hes3 Axis, a tumor mechanism we discovered that enables cancer to evade treatment and regrow. Recognized by Nature and Merck in 2024 and supported by over 20 years of research, we are now in the in vivo stage working with the UK’s leading Research Technology Organization, Medicines Discovery Catapult.
Prototype/preclinical
4.200.000€
2028-2029
Biotechnology
6.67%
1.000€
Share this project on your website.
Copy and paste the following code into your content.
Glioblastoma, a deadly brain cancer, typically leaves patients with a one-year life expectancy despite aggressive treatments. Current therapies fail to target cancer stem cells, which regenerate the tumor. Innate Repair Brain (iRB) has discovered a new approach targeting the Hes3 Signaling Axis, a pathway crucial for the survival of these stem cells. By blocking this pathway, our therapy eliminates the cancer stem cells, reducing tumor growth and recurrence. This solution works alongside surgery, radiation, and chemotherapy, offering a stronger defense and improving outcomes for glioblastoma patients.
Glioblastoma’s orphan disease status allows iRB to fast-track regulatory approval. With the glioma treatment market valued at $4.1 billion, it’s a key focus for iRB. Our technology, which targets the Hes3 Axis with high precision, could expand beyond glioblastoma into larger markets like prostate and breast cancers, worth over $100 billion. By using cutting-edge RNA therapeutics, we reduce the risk of side effects, positioning iRB at the forefront of biology and chemistry for years to come.
iRB’s approach has gained major attention in the scientific community, earning a spot on Nature Journal and Merck’s “Ones to Watch” list in July 2024. We’ve published in top journals like Nature and PNAS, and our research shows strong in vitro results with our target cells found in over 70% of glioblastoma patients. Our mouse models are also ready for in vivo studies. This has attracted interest from Big Pharma, with expected results in 12-18 months. Leading labs, including NIH, MIT, and Pfizer, have confirmed our findings.
Investing in iRB supports a targeted approach to a critical gap in glioblastoma care. The funding will position us for strategic collaborations with Big Pharma or acquisition as early as within 18 months.
Despite advances in oncology, cancer remains one of the world's leading causes of death. Glioblastoma, one of its most aggressive forms, has a high lethality and few effective treatment options. Current therapies target common tumor cells, but cancer stem cells (CSCs) can regenerate and resist these treatments, leading to cancer recurrence.
Innate Repair Brain has pioneered the discovery of the Hes3 axis as a key target to combat CSCs. Its studies have shown that more than 70% of glioblastoma patient biopsies contain these cells, reinforcing the potential of its therapeutic approach. Based on 20 years of research and multiple publications validated by scientists worldwide, they have developed advanced RNAi and biomarker therapies specifically targeting CSCs.
Its first candidate, iRSN, has demonstrated efficacy in vitro and already has in vivo mouse models for further preclinical testing. With patents in the US, UK, Germany and France, Innate Repair Brain has exclusive rights to use iRSN in brain cancer and is seeking funding to complete efficacy studies in animal models and establish collaborations with the pharmaceutical industry.
Capital Cell believes Innate Repair Brain addresses a critical need in the treatment of glioblastoma, offering an innovative approach with high potential for impact and return for investors.
Innate Repair Brain faces the challenge of taking its siRNA-based treatment from the research phase to clinical application. This process can be complicated, as it must demonstrate the efficacy and safety of iRSN in clinical trials, which requires significant time and resources.
In addition, obtaining regulatory approvals for your treatments can be a lengthy and complex process, which could delay the availability of your therapies on the market.
Already have an account? Please login here .
You can now make your investment without any commitment, and without making any payment.
Simply indicate the amount you want to invest, click "Continue" and complete the booking confirmation process. At this stage we will not ask you for any bank details or credit card number.
As soon as the campaign gains momentum and more investors show interest, we will contact you to formalize the payment, and you will have up to 5 days to confirm your investment and make the payment. Until then, you can cancel this reservation without any commitment.
Although this is a non-binding commitment, it does represent an investment interest. Before proceeding, be sure to read and understand the risks involved in this type of investment.
